FGFR inhibitors (FGFRi) benefit patients with FGFR2-fusion positive intrahepatic cholangiocarcinoma (ICC) but depth and duration of response is often limited. The gene discussed is FGFR2; the disease is intrahepatic cholangiocarcinoma.